Teva gets rights to BioAlliance's Sitavig in Israel
French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has signed an exclusive license agreement for Sitavig (acyclovir Lauriad) with Abic Marketing, a subsidiary of Teva Pharmaceutical Industries (Nasdaq: TEVA) for commercialization rights in Israel.
Financial terms of this license accord are not disclosed, but the companies noted that the deal includes upfront and milestone payments, as well as royalties on sales in Israel, to be paid to BioAlliance Pharma by Teva.
Sitavig is indicated for the treatment of recurrent labial herpes in immunocompetent patients presenting more than four episodes a year. Sitavig is based on the innovative mucoadhesive buccal technology Lauriad, delivering very high concentrations of acyclovir at the site of herpes infection. The Phase III trial (775 patients) has shown a strong efficacy and safety profile, basis for the registration submission.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze